Clinical role of micrornas in cytogenetically normal acute myeloid leukemia: MiR-155 Upregulation independently identifies high-risk patients

Journal of Clinical Oncology

Volumn 31, Issue 17, 2013, Pages 2086-2093

  Marcucci, Guido ^a   Maharry, Kati S ^a   Metzeler, Klaus H ^a   Volinia, Stefano ^a   Wu, Yue Zhong ^a   Mrozek, Krzysztof ^a   Nicolet, Deedra ^a   Kohlschmidt, Jessica ^a   Whitman, Susan P ^a   Mendler, Jason H ^a   Schwind, Sebastian ^a   Becker, Heiko ^a   Eisfeld, Ann Kathrin ^a   Carroll, Andrew J ^b   Powell, Bayard L ^c   Kolitz, Jonathan E ^d   Garzon, Ramiro ^e   Caligiuri, Michael A ^a   Stone, Richard M ^a   Bloomfield, Clara D ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c WAKE FOREST BAPTIST HEALTH   (United States)

^d North Shore Long Island Center for Advanced Medicine   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 155; ANTINEOPLASTIC AGENT; MIRN155 MICRORNA, HUMAN; TUMOR MARKER;

ACUTE MYELOID LEUKEMIA; ADULT; APOPTOSIS; ARTICLE; BONE MARROW; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOGENETICS; DISEASE FREE SURVIVAL; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HUMAN; INFLAMMATION; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; UPREGULATION; AGED; BIOSYNTHESIS; GENETIC PREDISPOSITION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTOGENETICS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; YOUNG ADULT;

EID: 84885424565     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.6228     Document Type: Article

References (48)

1. Garzon R, Marcucci G, Croce CM: Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov 9:775-789, 2010
2. Marcucci G, Mrozek K, Radmacher MD, et al: The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 117:1121-1129, 2011
3. Marcucci G, Radmacher MD, Maharry K, et al: MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1919-1928, 2008
4. Tili E, Michaille JJ, Wernicke D, et al: Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci U S A 108:4908-4913, 2011
5. O'Connell RM, Taganov KD, Boldin MP, et al: MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A 104:1604-1609, 2007
6. O'Connell RM, Rao DS, Chaudhuri AA, et al: Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 205:585-594, 2008
7. O'Connell RM, Chaudhuri AA, Rao DS, et al: Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A 106:7113-7118, 2009
8. Tili E, Croce CM, Michaille JJ: miR-155: On the crosstalk between inflammation and cancer. Int Rev Immunol 28:264-284, 2009
9. Costinean S, Sandhu SK, Pedersen IM, et al: Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood 114: 1374-1382, 2009
10. Garzon R, Volinia S, Liu C-G, et al: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111:3183-3189, 2008
11. Whitman SP, Maharry K, Radmacher MD, et al: FLT3 internal tandem duplication associates with adverse outcome and gene-and microRNAexpression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. Blood 116:3622-3626, 2010
12. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002
13. Schlenk RF, Dohner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358: 1909-1918, 2008
14. Obad S, dos Santos CO, Petri A, et al: Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43:371-378, 2011
15. Mro zek K, Carroll AJ, Maharry K, et al: Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience. Int J Oncol 33:239-244, 2008
16. Kolitz JE, George SL, Marcucci G, et al: P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients under age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 116:1413-1421, 2010
17. Kolitz JE, George SL, Dodge RK, et al: Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 22:4290-4301, 2004
18. Kolitz JE, George SL, Barrier R, et al: A novel post-remission consolidation regimen for patients with acute myeloid leukemia (AML) β 60 years old with normal or unfavorable cytogenetics: Results from CALGB 9621. Blood 102:175a, 2003 (abstr 609)
19. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903, 1994
20. Stone RM, Berg DT, George SL, et al: Postremission therapy in older patients with de novo acute myeloid leukemia: A randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98:548-553, 2001
21. Lee EJ, George SL, Caligiuri M, et al: Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of Cancer and Leukemia Group B study 9420. J Clin Oncol 17:2831-2839, 1999
22. Baer MR, George SL, Dodge RK, et al: Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B study 9720. Blood 100:1224-1232, 2002
23. Baer MR, George SL, Caligiuri MA, et al: Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B study 9720. J Clin Oncol 26:4934-4939, 2008
24. Marcucci G, Moser B, Blum W, et al: A phase III randomized trial of intensive induction and consolidation chemotherapy β oblimersen, a proapoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients β60 years old. J Clin Oncol 25:360s, 2007 (suppl; abstr 7012)
25. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
26. Payton JE, Grieselhuber NR, Chang LW, et al: High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest 119:1714-1726, 2009
27. Whitman SP, Ruppert AS, Radmacher MD, et al: FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct geneexpression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 111:1552-1559, 2008
28. Caligiuri MA, Strout MP, Schichman SA, et al: Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 56:1418-1425, 1996
29. Whitman SP, Ruppert AS, Marcucci G, et al: Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: A Cancer and Leukemia Group B study. Blood 109:5164-5167, 2007
30. Becker H, Marcucci G, Maharry K, et al: Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol 28:596-604, 2010
31. Marcucci G, Maharry K, Radmacher MD, et al: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B study. J Clin Oncol 26:5078-5087, 2008
32. Becker H, Marcucci G, Maharry K, et al: Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. Blood 116:788-792, 2010
33. Metzeler KH, Maharry K, Radmacher MD, et al: TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 29:1373-1381, 2011
34. Metzeler KH, Becker H, Maharry K, et al: ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 118:6920-6929, 2011
35. Marcucci G, Metzeler KH, Schwind S, et al: Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 30:742-750, 2012
36. Gaidzik VI, Bullinger L, Schlenk RF, et al: RUNX1 mutations in acute myeloid leukemia: Results from a comprehensive genetic and clinical analysis from the AML Study Group. J Clin Oncol 29:1364-1372, 2011
37. Mendler JH, Maharry K, Radmacher MD, et al: RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin Oncol 30:3109-3118, 2012
38. Marcucci G, Maharry K, Wu YZ, et al: IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 28:2348-2355, 2010
39. Schwind S, Marcucci G, Maharry K, et al: BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. Blood 116: 5660-5669, 2010
40. Schwind S, Maharry K, Radmacher MD, et al: Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 28:5257-5264, 2010
41. Langer C, Marcucci G, Holland KB, et al: Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 27:3198-3204, 2009
42. Hollander M, Wolfe DA: Nonparametric Statistical Methods. New York, NY, John Wiley & Sons, 1999
43. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:44-57, 2009
44. Agresti A: An Introduction to Categorical Data Analysis. New York, NY, John Wiley & Sons, 1996
45. Hosmer D, Lemeshow S: Applied Logistic Regression. New York, NY, John Wiley & Sons, 2000
46. Hosmer D, Lemeshow S, May S: Applied Survival Analysis. New York, NY, John Wiley & Sons, 2008
47. Dohner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
48. Mrozek K, Marcucci G, Nicolet D, et al: Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 30:4515-4523, 2012